Acrivon Therapeutics, Inc. (NASDAQ:ACRV) earns a spot on the list of 12 hot penny stocks due to strong performance and upside potential. H.C. Wainwright analyst initiates coverage with a “Buy” rating and $19 price target, citing positive outlook from pipeline developments, particularly the ACR-368 Phase 2b trial.

Q3 2025 results show Acrivon Therapeutics (ACRV) reporting a net loss of $18.2 million, an improvement from the previous year. R&D expenses focused on endometrial cancer decreased, with $134.4 million in cash reserves to fund operations. Progress in ACR-368 and ACR-2316 trials noted.

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biopharmaceutical company specializing in precision medicines developed through its Generative Phosphoproteomics AP3 platform.

While ACRV shows investment potential, AI stocks are seen to offer greater upside with lower risk. For an undervalued AI stock poised to benefit from current trends, explore a free report on the best short-term AI stock.

Read more at Yahoo Finance: H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT